Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664660 | 0.76 | NPC1 (0.33) | TACR1NPC1RAB9AKDM4ECCR5 | |
| SCHEMBL5656761 | 0.70 | PDK1 (0.32) | GSK3BMAPTKDM4EPPARGSMN1; SMN2 | |
| SCHEMBL5657349 | 0.69 | CXCR2 (0.32) | GSK3BPPARG | |
| SCHEMBL4664643 | 0.66 | CXCR2 (0.33) | GSK3BKDM4EPPARGSMN1; SMN2 | |
| SCHEMBL4662901 | 0.66 | CXCR2 (0.33) | GSK3BKDM4EPPARGSMN1; SMN2 | |
| SCHEMBL5138943 | 0.66 | CXCR2 (0.33) | GSK3BKDM4EPPARGSMN1; SMN2 | |
| SCHEMBL4664676 | 0.65 | CXCR2 (0.34) | NPC1RAB9AKDM4EPPARG | |
| SCHEMBL4664608 | 0.65 | PDK1 (0.32) | GSK3BNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4664836 | 0.63 | PARP1 (0.35) | KDM4ECCR5CYP1A2CYP2D6 | |
| SCHEMBL5427750 | 0.62 | CXCR2 (0.34) | PPARGSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1613626-A1 | CYCLIC BENZIMIDAZOLES | ALTANA Pharma AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087701-A1 | CYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | TACR1 1850/4885GSK3B 3676/4885ACSS2 1517/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | TACR1 1133/4885GSK3B 2991/4885ACSS2 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.